Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of two corticosteroids (triamcinolone and betamethasone) used primarily for the treatment of inflammatory conditions, particularly keloids. This combination leverages the anti-inflammatory, anti-allergic, and tissue proliferation inhibitory properties of both medications.\n\nStudies have shown that sequential treatment with triamcinolone acetonide combined with compound betamethasone was more effective than compound betamethasone alone for keloid treatment, with a total effective rate of 82% compared to 54% for the control group. Both medications individually are used for a wide range of inflammatory and allergic conditions. When used together for keloid treatment, the medications are administered as sequential injections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamcinolone + betamethasone.